Highly Active Myeloid Therapy for Cancer
- 12 October 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (20) , 20666-20679
Abstract
Tumor-associated macrophages (TAM) interact with cancer and stromal cells and are integral to sustaining many cancer-promoting features. Therapeutic manipulation of TAM could therefore improve clinical outcomes and synergize with immunotherapy and other cancer therapies. While different nanocarriers have been used to target TAM, a knowledge gap exists on which TAM pathways to target and what payloads to deliver for optimal antitumor effects. We hypothesized that a multipart combination involving the Janus tyrosine kinase (JAK), noncanonical nuclear factor kappa light chain enhancer of activated B cells (NF-κB), and toll-like receptor (TLR) pathways could lead to a highly active myeloid therapy (HAMT). Thus, we devised a screen to determine drug combinations that yield maximum IL-12 production from myeloid cells to treat the otherwise highly immunosuppressive myeloid environments in tumors. Here we show the extraordinary efficacy of a triple small-molecule combination in a TAM-targeted nanoparticle for eradicating murine tumors, jumpstarting a highly efficient antitumor response by adopting a distinctive antitumor TAM phenotype and synergizing with other immunotherapies. The HAMT therapy represents a recently developed approach in immunotherapy and leads to durable responses in murine cancer models.Keywords
Funding Information
- National Cancer Institute (P01CA069246, R01CA281735)
- Boehringer Ingelheim Fonds
- Schweizerischer Nationalfonds zur F?rderung der Wissenschaftlichen Forschung (P500PN_210730)
This publication has 54 references indexed in Scilit:
- Promising applications in drug delivery systems of a novel β-cyclodextrin derivative obtained by green synthesisBioorganic & Medicinal Chemistry Letters, 2016
- Characterizing the Interactions of Organic Nanoparticles with Renal Epithelial Cellsin VivoACS Nano, 2015
- Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulationsProceedings of the National Academy of Sciences, 2014
- Imaging windows for long-term intravital imagingIntraVital, 2014
- Interleukin 12: still a promising candidate for tumor immunotherapy?Cancer Immunology, Immunotherapy, 2014
- CSF-1R inhibition alters macrophage polarization and blocks glioma progressionNature Medicine, 2013
- Inhibition of JAKs in Macrophages Increases Lipopolysaccharide-Induced Cytokine Production by Blocking IL-10–Mediated FeedbackThe Journal of Immunology, 2012
- IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumorsJournal of Clinical Investigation, 2011
- Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer PatientsClinical Cancer Research, 2011
- A phase I clinical trial of imiquimod, an oral interferon inducer, administered dailyBritish Journal of Cancer, 1996